The VPS35 gene and Parkinson's disease

Movement Disorders

Volumn 28, Issue 5, 2013, Pages 569-575

  Deng, Hao ^a   Gao, Kai ^a   Jankovic, Joseph ^b  

^a CENTRAL SOUTH UNIVERSITY   (China)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

DMT1; Parkinson's disease; Retromer; VPS35; Wnt

Indexed keywords

BETA CATENIN; LEUCINE RICH REPEAT KINASE 2; MESSENGER RNA; NATURAL RESISTANCE ASSOCIATED MACROPHAGE PROTEIN 2; PARKIN; WNT PROTEIN;

BALANCE DISORDER; BRADYKINESIA; CHROMOSOME 16Q; CLINICAL FEATURE; EXOME; GENE; GENE FREQUENCY; GENE MUTATION; GENETIC VARIABILITY; HETEROZYGOTE; HUMAN; ISOELECTRIC POINT; LYSOSOME MEMBRANE; NONHUMAN; ONSET AGE; PARKINSON DISEASE; PENETRANCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; RIGIDITY; TRANS GOLGI NETWORK; TREMOR; VPS35 GENE; WNT SIGNALING PATHWAY;

ANIMALS; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MALE; MUTATION; PARKINSON DISEASE; TRANSCRIPTION FACTORS; VESICULAR TRANSPORT PROTEINS;

EID: 84877923497     PISSN: 08853185     EISSN: 15318257     Source Type: Journal    
DOI: 10.1002/mds.25430     Document Type: Review

References (76)

1. de Lau LM, Breteler MM. Epidemiology of Parkinson's disease. Lancet Neurol. 2006;5:525-535.
2. Jankovic J. Parkinson's disease: clinical features and diagnosis. J Neurol Neurosurg Psychiatry. 2008;79:368-376.
3. Rodriguez-Oroz MC, Jahanshahi M, Krack P, et al. Initial clinical manifestations of Parkinson's disease: features and pathophysiological mechanisms. Lancet Neurol. 2009;8:1128-1139.
4. Jankovic J, Poewe W. Therapies in Parkinson's disease. Curr Opin Neurol. 2012;25:433-447.
5. Kasten M, Chade A, Tanner CM. Epidemiology of Parkinson's disease. Handb Clin Neurol. 2007;83:129-151.
6. Deng H, Liang H, Jankovic J. F-box only protein 7 gene in parkinsonian-pyramidal disease. Arch Neurol. 2012;70:20-24.
7. Lesage S, Brice A. Role of Mendelian genes in "sporadic" Parkinson's disease. Parkinsonism Relat Disord. 2012;18(Suppl 1):S66-S70.
8. Vilarino-Guell C, Wider C, Ross OA, et al. VPS35 mutations in Parkinson disease. Am J Hum Genet. 2011;89:162-167.
9. Zimprich A, Benet-Pages A, Struhal W, et al. A mutation in VPS35, encoding a subunit of the retromer complex, causes late-onset Parkinson disease. Am J Hum Genet. 2011;89:168-175.
10. Verstraeten A, Wauters E, Crosiers D, et al. Contribution of VPS35 genetic variability to LBD in the Flanders-Belgian population. Neurobiol Aging. 2012;33:1811-1844.
11. Sheerin UM, Charlesworth G, Bras J, et al. Screening for VPS35 mutations in Parkinson's disease. Neurobiol Aging. 2012;33:831-838.
12. Guella I, Solda G, Cilia R, et al. The Asp620asn mutation in VPS35 is not a common cause of familial Parkinson's disease. Mov Disord. 2012;27:800-801.
13. Zhang Y, Chen S, Xiao Q, et al. Vacuolar protein sorting 35 Asp620Asn mutation is rare in the ethnic Chinese population with Parkinson's disease. Parkinsonism Relat Disord. 2012;18:638-640.
14. Guo JF, Sun QY, Lv ZY, et al. VPS35 gene variants are not associated with Parkinson's disease in the mainland Chinese population. Parkinsonism Relat Disord. 2012;18:983-985.
15. Lesage S, Condroyer C, Klebe S, et al. Identification of VPS35 mutations replicated in French families with Parkinson disease. Neurology. 2012;78:1449-1450.
16. Kumar KR, Weissbach A, Heldmann M, et al. Frequency of the D620N Mutation in VPS35 in Parkinson Disease. Arch Neurol. 2012;69:1360-1364.
17. Deng H, Xu H, Deng X, et al. VPS35 mutation in Chinese Han patients with late-onset Parkinson's disease. Eur J Neurol. 2012;19:e96-e97.
18. Ando M, Funayama M, Li Y, et al. VPS35 mutation in Japanese patients with typical Parkinson's disease. Mov Disord. 2012;27:1413-1417.
19. Sharma M, Ioannidis JP, Aasly JO, et al. A multi-centre clinico-genetic analysis of the VPS35 gene in Parkinson disease indicates reduced penetrance for disease-associated variants. J Med Genet. 2012;49:721-726.
20. Chen Y, Chen K, Song W, et al. VPS35 Asp620Asn and EIF4G1 Arg1205His mutations are rare in Parkinson disease from Southwest China. Neurobiol Aging. 2013;34:1709.e7-1709.e8.
21. Khan NL, Jain S, Lynch JM, et al. Mutations in the gene LRRK2 encoding dardarin (PARK8) cause familial Parkinson's disease: clinical, pathological, olfactory and functional imaging and genetic data. Brain. 2005;128:2786-2796.
22. Toft M, Mata IF, Kachergus JM, Ross OA, Farrer MJ. LRRK2 mutations and Parkinsonism. Lancet. 2005;365:1229-1230.
23. Benamer HT, de Silva R, Siddiqui KA, Grosset DG. Parkinson's disease in Arabs: a systematic review. Mov Disord. 2008;23:1205-1210.
24. Edgar AJ, Polak JM. Human homologues of yeast vacuolar protein sorting 29 and 35. Biochem Biophys Res Commun. 2000;277:622-630.
25. Zhang P, Yu L, Gao J, et al. Cloning and characterization of human VPS35 and mouse Vps35 and mapping of VPS35 to human chromosome 16q13-q21. Genomics. 2000;70:253-257.
26. Attar N, Cullen PJ. The retromer complex. Adv Enzyme Regul. 2010;50:216-236.
27. McGough IJ, Cullen PJ. Recent advances in retromer biology. Traffic. 2011;12:963-971.
28. Rojas R, Kametaka S, Haft CR, Bonifacino JS. Interchangeable but essential functions of SNX1 and SNX2 in the association of retromer with endosomes and the trafficking of mannose 6-phosphate receptors. Mol Cell Biol. 2007;27:1112-1124.
29. Bonifacino JS, Hurley JH. Retromer. Curr Opin Cell Biol. 2008;20:427-436.
30. Anitei M, Hoflack B. Exit from the trans-Golgi network: from molecules to mechanisms. Curr Opin Cell Biol. 2011;23:443-451.
31. Arighi CN, Hartnell LM, Aguilar RC, Haft CR, Bonifacino JS. Role of the mammalian retromer in sorting of the cation-independent mannose 6-phosphate receptor. J Cell Biol. 2004;165:123-133.
32. Griffin CT, Trejo J, Magnuson T. Genetic evidence for a mammalian retromer complex containing sorting nexins 1 and 2. Proc Natl Acad Sci U S A. 2005;102:15173-15177.
33. Chen D, Xiao H, Zhang K, et al. Retromer is required for apoptotic cell clearance by phagocytic receptor recycling. Science. 2010;327:1261-1264.
34. Harterink M, Port F, Lorenowicz MJ, et al. A SNX3-dependent retromer pathway mediates retrograde transport of the Wnt sorting receptor Wntless and is required for Wnt secretion. Nat Cell Biol. 2011;13:914-923.
35. Hierro A, Rojas AL, Rojas R, et al. Functional architecture of the retromer cargo-recognition complex. Nature. 2007;449:1063-1067.
36. Restrepo R, Zhao X, Peter H, Zhang BY, Arvan P, Nothwehr SF. Structural features of vps35p involved in interaction with other subunits of the retromer complex. Traffic. 2007;8:1841-1853.
37. Zhao X, Nothwehr S, Lara-Lemus R, Zhang BY, Peter H, Arvan P. Dominant-negative behavior of mammalian Vps35 in yeast requires a conserved PRLYL motif involved in retromer assembly. Traffic. 2007;8:1829-1840.
38. Haft CR, de la Luz SM, Bafford R, Lesniak MA, Barr VA, Taylor SI. Human orthologs of yeast vacuolar protein sorting proteins Vps26, 29, and 35: assembly into multimeric complexes. Mol Biol Cell. 2000;11:4105-4116.
39. Collins BM, Skinner CF, Watson PJ, Seaman MN, Owen DJ. Vps29 has a phosphoesterase fold that acts as a protein interaction scaffold for retromer assembly. Nat Struct Mol Biol. 2005;12:594-602.
40. Small SA, Kent K, Pierce A, et al. Model-guided microarray implicates the retromer complex in Alzheimer's disease. Ann Neurol. 2005;58:909-919.
41. Bhalla A, Vetanovetz CP, Morel E, Chamoun Z, Di Paolo G, Small SA. The location and trafficking routes of the neuronal retromer and its role in amyloid precursor protein transport. Neurobiol Dis. 2012;47:126-134.
42. Muhammad A, Flores I, Zhang H, et al. Retromer deficiency observed in Alzheimer's disease causes hippocampal dysfunction, neurodegeneration, and Aβ accumulation. Proc Natl Acad Sci U S A. 2008;105:7327-7332.
43. Wen L, Tang FL, Hong Y, et al. VPS35 haploinsufficiency increases Alzheimer's disease neuropathology. J Cell Biol. 2011;195:765-779.
44. Wang CL, Tang FL, Peng Y, Shen CY, Mei L, Xiong WC. VPS35 regulates developing mouse hippocampal neuronal morphogenesis by promoting retrograde trafficking of BACE1. Biol Open. 2012;1:1248-1257.
45. Castelo-Branco G, Wagner J, Rodriguez FJ, et al. Differential regulation of midbrain dopaminergic neuron development by Wnt-1, Wnt-3a, and Wnt-5a. Proc Natl Acad Sci USA. 2003;100:12747-12752.
46. Inestrosa NC, Arenas E. Emerging roles of Wnts in the adult nervous system. Nat Rev Neurosci. 2010;11:77-86.
47. Dun Y, Li G, Yang Y, et al. Inhibition of the canonical Wnt pathway by Dickkopf-1 contributes to the neurodegeneration in 6-OHDA-lesioned rats. Neurosci Lett. 2012;525:83-88.
48. L'Episcopo F, Tirolo C, Testa N, et al. Reactive astrocytes and Wnt/β-catenin signaling link nigrostriatal injury to repair in 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine model of Parkinson's disease. Neurobiol Dis. 2011;41:508-527.
49. Ohnuki T, Nakamura A, Okuyama S, Nakamura S. Gene expression profiling in progressively MPTP-lesioned macaques reveals molecular pathways associated with sporadic Parkinson's disease. Brain Res. 2010;1346:26-42.
50. Cantuti-Castelvetri I, Keller-McGandy C, Bouzou B, et al. Effects of gender on nigral gene expression and Parkinson disease. Neurobiol Dis. 2007;26:606-614.
51. De Ferrari GV, Chacón MA, Barría MI, Garrido JL, et al. Activation of Wnt signaling rescues neurodegeneration and behavioral impairments induced by beta-amyloid fibrils. Mol Psychiatry. 2003;8:195-208.
52. L'Episcopo F, Serapide MF, Tirolo C, et al. A Wnt1 regulated Frizzled-1/β-Catenin signaling pathway as a candidate regulatory circuit controlling mesencephalic dopaminergic neuron-astrocyte crosstalk: Therapeutical relevance for neuron survival and neuroprotection. Mol Neurodegener. 2011;13:6:49.
53. Rawal N, Corti O, Sacchetti P, et al. Parkin protects dopaminergic neurons from excessive Wnt/beta-catenin signaling. Biochem Biophys Res Commun. 2009;388:473-478.
54. Sancho RM, Law BM, Harvey K. Mutations in the LRRK2 Roc-COR tandem domain link Parkinson's disease to Wnt signalling pathways. Hum Mol Genet. 2009;18:3955-3968.
55. Corti O, Lesage S, Brice A. What genetics tells us about the causes and mechanisms of Parkinson's disease. Physiol Rev. 2011;91:1161-1218.
56. Banziger C, Soldini D, Schutt C, Zipperlen P, Hausmann G, Basler K. Wntless, a conserved membrane protein dedicated to the secretion of Wnt proteins from signaling cells. Cell. 2006;125:509-522.
57. Bartscherer K, Pelte N, Ingelfinger D, Boutros M. Secretion of Wnt ligands requires Evi, a conserved transmembrane protein. Cell. 2006;125:523-533.
58. Belenkaya TY, Wu Y, Tang X, et al. The retromer complex influences Wnt secretion by recycling wntless from endosomes to the trans-Golgi network. Dev Cell. 2008;14:120-131.
59. Franch-Marro X, Wendler F, Guidato S, et al. Wingless secretion requires endosome-to-Golgi retrieval of Wntless/Evi/Sprinter by the retromer complex. Nat Cell Biol. 2008;10:170-177.
60. Port F, Kuster M, Herr P, et al. Wingless secretion promotes and requires retromer-dependent cycling of Wntless. Nat Cell Biol. 2008;10:178-185.
61. Donovan A, Roy CN, Andrews NC. The ins and outs of iron homeostasis. Physiology (Bethesda). 2006;21:115-123.
62. Benarroch EE. Brain iron homeostasis and neurodegenerative disease. Neurology. 2009;72:1436-1440.
63. Dusek P, Jankovic J, Le W. Iron dysregulation in movement disorders. Neurobiol Dis. 2012;46:1-18.
64. Jiang H, Song N, Xu H, Zhang S, Wang J, Xie J. Up-regulation of divalent metal transporter 1 in 6-hydroxydopamine intoxication is IRE/IRP dependent. Cell Res. 2010;20:345-356.
65. Salazar J, Mena N, Hunot S, et al. Divalent metal transporter 1 (DMT1) contributes to neurodegeneration in animal models of Parkinson's disease. Proc Natl Acad Sci USA. 2008;105:18578-18583.
66. Zhang S, Wang J, Song N, Xie J, Jiang H. Up-regulation of divalent metal transporter 1 is involved in 1-methyl-4-phenylpyridinium (MPP(+))-induced apoptosis in MES23.5 cells. Neurobiol Aging. 2009;30:1466-1476.
67. He Q, Du T, Yu X, et al. DMT1 polymorphism and risk of Parkinson's disease. Neurosci Lett. 2011;501:128-131.
68. Chew KC, Ang ET, Tai YK, et al. Enhanced autophagy from chronic toxicity of iron and mutant A53T alpha-synuclein: implications for neuronal cell death in Parkinson disease. J Biol Chem. 2011;286:33380-33389.
69. Auluck PK, Caraveo G, Lindquist S. alpha-Synuclein: membrane interactions and toxicity in Parkinson's disease. Annu Rev Cell Dev Biol. 2010;26:211-233.
70. Roth JA, Singleton S, Feng J, Garrick M, Paradkar PN. Parkin regulates metal transport via proteasomal degradation of the 1B isoforms of divalent metal transporter 1. J Neurochem. 2010;113:454-464.
71. Tabuchi M, Yanatori I, Kawai Y, Kishi F. Retromer-mediated direct sorting is required for proper endosomal recycling of the mammalian iron transporter DMT1. J Cell Sci. 2010;123:756-766.
72. Lesage S, Brice A. Parkinson's disease: from monogenic forms to genetic susceptibility factors. Hum Mol Genet. 2009;18:R48-R59.
73. Esposito G, Ana Clara F, Verstreken P. Synaptic vesicle trafficking and Parkinson's disease. Dev Neurobiol. 2012;72:134-144.
74. Tofaris GK. Lysosome-dependent pathways as a unifying theme in Parkinson's disease. Mov Disord. 2012;27:1364-1369.
75. Hausmann G, Banziger C, Basler K. Helping Wingless take flight: how WNT proteins are secreted. Nat Rev Mol Cell Biol. 2007;8:331-336.
76. Yang PT, Lorenowicz MJ, Silhankova M, Coudreuse DY, Betist MC, Korswagen HC. Wnt signaling requires retromer-dependent recycling of MIG-14/Wntless in Wnt-producing cells. Dev Cell. 2008;14:140-147.